Proton Pump Inhibitors and Gastric Disease Push Fasting Gastrin Higher in Endoscopy Cohort
Hypergastrinaemia is not a diagnosis in itself, but it can be the biochemical trail that leads clinicians toward one. In everyday practice, the more common explanations are far less dramatic than gastrinoma: proton pump inhibitor therapy, Helicobacter pylori infection, and the mucosal injury that accompanies gastric preneoplastic pathology. This study set out to measure how those factors behave in the same clinical population, rather than in isolation.
The setting was a large diagnostic endoscopy service. Investigators measured fasting serum gastrin by radioimmunoassay in 1,400 patients undergoing oesophagogastro-duodenoscopy, then narrowed the analytic cohort to 982 after exclusions. Patients were separated into four clinically meaningful groups: a normal group with no H. pylori infection, no PPI use, and no histological evidence of gastric preneoplasia; a group taking regular PPIs; a group with active H. pylori infection but no gastric preneoplasia; and a group with histologically confirmed gastric preneoplasia.
The design matters because gastrin is tightly tied to gastric acid physiology. When acid secretion is suppressed, G cells respond by increasing gastrin output. When chronic infection or premalignant mucosal change alters the gastric glandular environment, the feedback loop becomes distorted in a different way. The clinical question is not whether gastrin rises, but how much each common driver contributes when patients overlap in real-world endoscopy practice.
Baseline Physiology Was Already Disturbed Before the First Blood Draw
The normal group established the reference point. Median fasting gastrin concentration was 20 pM in patients without H. pylori, without PPI exposure, and without histological preneoplasia. Among regular PPI users who were H. pylori negative and had no preneoplastic change, the median fasting gastrin concentration rose to 46 pM, with a significant difference from the normal group.
A single therapeutic class created a biochemical shift large enough to separate one group from another at the median level. In a clinic, that is the sort of finding that can complicate evaluation of incidental hypergastrinaemia, especially when the medication history is incomplete or when the drug is stopped only briefly before testing. Acid suppression is the most straightforward mechanism here: when the stomach is pharmacologically silenced, gastrin output rises as the normal inhibitory feedback loop weakens.
In practical terms, this is why fasting gastrin cannot be interpreted in a vacuum. A patient on a PPI may look biochemically abnormal for reasons that are entirely medication-related, even before infection or mucosal pathology are considered.
H. pylori and Preneoplastic Change Add a Second Layer of Gastric Feedback Distortion
Patients with active H. pylori infection but no gastric preneoplasia formed the third analytic group, and patients with histologically confirmed gastric preneoplasia formed the fourth. Both groups were included because each can alter gastric physiology through different biological routes. Infection changes inflammatory signaling and mucosal function. Preneoplastic pathology changes the structure and secretory capacity of the gastric lining itself.
Those processes are not interchangeable. H. pylori can drive chronic gastritis and shift the acid-gastrin axis through ongoing inflammatory injury, while atrophic or preneoplastic change can remove the normal cellular machinery that keeps gastrin and acid secretion in balance. In the endoscopy suite, the distinction matters because a raised gastrin level may reflect medication effect, infection, or histologic disease — and the corrective action is different for each.
The study was built to separate those categories rather than blur them together. That approach is clinically useful because it mirrors the way gastroenterologists actually sort patients: medication exposure first, infection status second, and histology when endoscopic sampling is available.
Why the Gastrin Signal Matters at the Bedside
Fasting gastrin is often treated as a specialized test reserved for rare endocrine disease, yet this cohort shows how often common upper gastrointestinal conditions can push the result upward. In a patient under evaluation for dyspepsia, reflux, unexplained mucosal change, or endoscopic surveillance, an elevated level should prompt a search for benign causes before any leap toward gastrinoma is made. PPI therapy alone can move the value substantially above the normal median, and the presence of H. pylori or preneoplastic pathology adds more context to the interpretation.
The biological logic is straightforward. Gastrin is part of a feedback circuit designed to preserve acid balance and coordinate gastric function. When acid is suppressed, gastrin secretion rises. When the mucosa is injured or altered by infection and preneoplastic change, the same circuit no longer behaves normally. The result is not a single mechanism but a layered perturbation of the same endocrine axis.
For clinicians, the central message is interpretive discipline. A raised gastrin concentration in a patient undergoing endoscopy does not immediately imply a gastrinoma, and this study reinforces that reality using a large diagnostic cohort drawn from routine practice.
Endoscopy Cohorts Capture the Messiness of Real Practice
One strength of the work is its setting. Diagnostic endoscopy cohorts are messy in the best possible way: they include patients taking acid suppression, patients with active infection, and patients whose gastric histology is already abnormal. That makes the findings more relevant to day-to-day gastroenterology than a narrowly selected experimental sample would be.
The cohort size was also substantial. After exclusions, 982 patients remained for analysis, allowing the investigators to compare four clinically distinct categories rather than forcing a simplistic infected-versus-uninfected or treated-versus-untreated comparison. That structure improves interpretability because gastrin is rarely influenced by only one factor.
Still, the results should be read with the same care used to order the test in the first place. Fasting gastrin is a marker shaped by medication exposure, infection, and histology, and the combined effect can complicate interpretation even when the assay itself is precise. The study used radioimmunoassay, which is appropriate for this purpose, but the assay cannot solve the underlying clinical ambiguity created by overlapping gastric conditions.
What Clinicians Should Take From the Pattern
The most immediate implication is diagnostic rather than therapeutic. In patients with elevated fasting gastrin, PPI exposure must be accounted for before overcalling endocrine disease. Active H. pylori infection and gastric preneoplastic pathology also belong in the differential, especially when endoscopy or histology is already part of the workup.
One sentence captures the clinical utility of the study: common gastric disorders can mimic the biochemical signature of rarer acid-related pathology.
The report does not support a one-size-fits-all interpretation of gastrin. It shows a layered physiology in which medication, infection, and mucosal change each exert influence, sometimes in the same patient. For that reason, a fasting gastrin value should be read alongside drug history, H. pylori status, and histological findings rather than in isolation.
The study leaves no room for casual interpretation of a mildly or moderately raised gastrin level in an endoscopy population. The test is useful, but only when the gastric context is known.